The Angelalign patent ruling concerns a discontinued feature and does not affect the availability of its current European offering, the clear-aligner maker said in an October 16, 2026 announcement. Angelalign Technology said it had already replaced Torque Ridges in Europe with Pressure Points before the Paris Local Division of the Unified Patent Court found that Torque Ridges infringed an Align Technology patent.
Key Takeaways
- Angelalign says its current European offering remains available after the ruling.
- Pressure Points replaced Torque Ridges in Europe following its September 2026 launch.
- The company disputes the decision but will comply while reviewing its options.
Table of Contents
- What the Angelalign patent ruling covers
- Replacement technology was launched before the decision
- Customer assurances do not quantify financial exposure
- Conclusion
What the Angelalign patent ruling covers
The court found that Torque Ridges infringed an Align Technology patent for repositioning a patient's teeth according to an orthodontic treatment plan, Angelalign said. The company's announcement describes a ruling concerning that feature, rather than a restriction on its entire clear-aligner offering.
Angelalign said it disagreed with the decision and was reviewing the court's reasoning while evaluating its options. It nevertheless committed to complying with the ruling, including the return of any products. The announcement did not confirm that an appeal had been filed.
| Item | Details |
|---|---|
| Announcement timing | October 16, 2026 US dateline; published October 17 in GMT+08:00. |
| Court | Paris Local Division of the Unified Patent Court. |
| Patent holder | Align Technology. |
| Replacement launch | Pressure Points launched in Europe in September 2026. |
Replacement technology was launched before the decision
In its European product transition announcement, Angelalign said Pressure Points launched in September 2026 and had already replaced Torque Ridges in Europe. The company described the replacement as designed to improve torque control; that is its stated product objective, not a clinical finding established by the court ruling.
Xavier Cherbavaz, Angelalign's general manager and vice president for Europe, Africa and the Middle East, said the replacement was intended to support controlled force application and tooth contact. The company said orthodontists could continue treating patients with Pressure Points and ongoing clinical and technical support.
Customer assurances do not quantify financial exposure
Angelalign said customers in Spain, the UK and outside Europe, including the Americas and Asia, were unaffected. Its assurance about continued availability reflects the company's assessment of the product transition, rather than an independent finding about customer impact.
The announcement did not quantify potential costs, product returns or any effect on revenue. Continued access to the replacement feature therefore does not, by itself, establish that the ruling has no financial consequences.
Conclusion
Angelalign's stated next steps are to comply with the ruling and review its legal options. Its announcement leaves the scale of any product returns and financial costs unquantified.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
